With reference to intimation of May 15, 2025, regarding the proposed Scheme of Arrangement for Demerger involving Arco Lab, wholly owned subsidiary of Strides and Pivot Path, wholly owned subsidiary of Arco Lab. The Scheme provides for the demerger of Arco Lab’s Life Sciences business and Digital Innovation business (the Demerged Undertaking) into Pivot Path, pursuant to Sections 230–232 of the Companies Act, 2013 and other applicable provisions of the Act and the Rules framed thereunder (Scheme); Strides Pharma Science has informed that the aforesaid Scheme was listed for pronouncement of order before the Hon’ble National Company Law Tribunal, Bengaluru Bench (NCLT) on May 18, 2026, and the NCLT has approved the said Scheme. The final order approving the demerger was made available on the NCLT portal on May 20, 2026.
The above information is a part of company’s filings submitted to BSE.
